Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Yaya Chu, Aliza Gardenswartz, Amanda Termuhlen, Mitchell S. Cairo

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

Original languageEnglish (US)
Pages (from-to)1055-1070
Number of pages16
JournalBritish Journal of Haematology
Volume185
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Bispecific Antibodies
Antigen Receptors
B-Cell Lymphoma
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
T-Cell Antigen Receptor
Hodgkin Disease
Natural Killer Cells
Netherlands
Non-Hodgkin's Lymphoma
Immunotherapy
Young Adult
T-Lymphocytes
Transplants
Population
Therapeutics

Keywords

  • B-cell non-Hodgkin lymphoma
  • IL-15 superagonist
  • cellular immunotherapy
  • chimeric antigen receptor
  • stem cell transplantation

Cite this

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. / Chu, Yaya; Gardenswartz, Aliza; Termuhlen, Amanda; Cairo, Mitchell S.

In: British Journal of Haematology, Vol. 185, No. 6, 01.06.2019, p. 1055-1070.

Research output: Contribution to journalReview article

@article{5bb429177033480aac7b1f7491d8f202,
title = "Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma",
abstract = "Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.",
keywords = "B-cell non-Hodgkin lymphoma, IL-15 superagonist, cellular immunotherapy, chimeric antigen receptor, stem cell transplantation",
author = "Yaya Chu and Aliza Gardenswartz and Amanda Termuhlen and Cairo, {Mitchell S.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1111/bjh.15753",
language = "English (US)",
volume = "185",
pages = "1055--1070",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

AU - Chu, Yaya

AU - Gardenswartz, Aliza

AU - Termuhlen, Amanda

AU - Cairo, Mitchell S.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

AB - Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th–29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

KW - B-cell non-Hodgkin lymphoma

KW - IL-15 superagonist

KW - cellular immunotherapy

KW - chimeric antigen receptor

KW - stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85059561682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059561682&partnerID=8YFLogxK

U2 - 10.1111/bjh.15753

DO - 10.1111/bjh.15753

M3 - Review article

VL - 185

SP - 1055

EP - 1070

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -